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The mechanisms contributing to bleeding com-
plications in dengue hemorrhagic fever were
studied by investigating the pattern of activation
of the coagulation and fibrinolytic systems in 50
children with severe dengue hemorrhagic fever.
Thirteen patients (26%) died, and activation of
coagulation was most pronounced in the de-
ceasedgroup. Fibrinolysiswasalsoactivated, but
this activationwas relativelyweakcomparedwith
that of coagulation as a result of persistently high
plasminogen activator inhibitor levels. Plasmino-
gen activator inhibitor also prevented a switch
from the procoagulant to the profibrinolytic state
in lethal dengue hemorrhagic fever, which was
further enhanced by an acquired protein C defi-
ciency. The present study is the first to demon-
strate such a mechanism in a viral infection. This
imbalance between coagulation and fibrinolysis
may be used as a prognostic marker, but it may
also be a target for future therapeutic interven-
tion. J. Med. Virol. 67:549–554, 2002.
 2002 Wiley-Liss, Inc.
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INTRODUCTION
Dengue fever is the most prevalent viral disease
transmitted by arthropod vectors worldwide [Perez-
Rigau et al., 1998]. The clinical picture varies from mild,
uncomplicated dengue fever to dengue hemorrhagic
fever and dengue shock syndrome. Dengue virus infec-
tions form a major and growing health care problem
worldwide, especially in endemic areas such as South
East Asia and Latin America. Each year millions of
people are infected, and about 250,000–500,000
patients develop severe dengue hemorrhagic fever,
accompanied by a mortality rate of 1–10% [Hayes and
Gubler, 1992; Gubler and Trent, 1993; Perez-Rigau
et al., 1998].
Limited data suggest that activation of coagulation
and fibrinolysis play a role in the pathogenesis of
dengue hemorrhagic fever [Srichaikul et al., 1977; Bha-
marapravati, 1989; Huang et al., 2001; van Gorp et al.,
2001]. However, the pathogenetic mechanism under-
lying bleeding complications and multiorgan failure
has not yet been elucidated. Systemic infections in
general may influence hemostasis, leading to thrombo-
hemorrhagic complications and disseminated intravas-
cular coagulation (DIC), hemolytic uremic syndrome,
thrombotic thrombocytopenic purpura, or vasculitis.
Bleeding or thrombosis, or both, may be dominant
symptoms. DIC may contribute to multiorgan failure
and is associated with a high mortality [ten Cate et al.,
1993; Bauer and Weitz, 1994; Levi and ten Cate, 1999].
However, current insights into the relationship be-
tween infectious diseases and the coagulation system
are based mainly on data obtained from clinical and
experimental studies of bacterial sepsis and little is
known about the relevance of this system in severe
viral infections [Cosgriff, 1989; van Gorp et al., 1999].
A curative treatment or vaccine for severe dengue
virus infections and other viral hemorrhagic pathogens
Grant sponsor: Royal Netherlands Academy of Arts and
Sciences (KNAW); Grant sponsor: Netherlands Heart Foundation;
Grant number: D98.013.
*Correspondence to: Dr. Eric C.M. van Gorp, Slotervaart
Hospital, Department of Internal Medicine (9B), Louwesweg 6,
1066 EC Amsterdam, The Netherlands.
E-mail: ecmvangorp@yahoo.co.uk
Accepted 13 February 2002
DOI 10.1002/jmv.10137
Published online in Wiley InterScience
(www.interscience.wiley.com)
 2002 WILEY-LISS, INC.
is not available, which underlines the need to under-
stand the pathogenesis of these infections. In the
present prospective longitudinal study we investigated
the balance between the activation patterns of the
coagulation and fibrinolytic systems in the course of
severe dengue hemorrhagic fever.
MATERIALS AND METHODS
Study Setting
The study was undertaken at the Dr. Kariadi
University Hospital of the University of Diponegoro,
in Semarang, Central Java, Indonesia, where dengue is
endemic and is known to cause yearly outbreaks.
Patients and Monitoring
Consecutive patients (children) admitted to the pedia-
tric intensive care unit, with a clinical diagnosis of
severe dengue hemorrhagic fever (grade III–IV)
according to criteria of the World Health Organization
[WHO, 1997], were included. In brief, the clinical
diagnosis of dengue hemorrhagic fever grade III was
based on the presence of fever, a hemorrhagic tendency,
plasma leakage manifested by pleural effusion, and/or a
rise in hematocrit ( 20%), thrombocytopenia (<100
109/L), and evidence of circulatory failure manifested
by a narrowing pulse pressure (20 mm Hg) or clinical
signs of shock with the presence of a cold clammy skin.
Those with profound shock were diagnosed as dengue
hemorrhagic fever grade IV.
To evaluate coagulation activity, the following tests
were carried out: activated partial thromboplastin
time, prothrombin time, fibrinogen, prothrombin frag-
ment 1þ 2, thrombin–antithrombin complexes, protein
C, and protein S. Fibrinolytic activity was evaluated by
the measurement of tissue-type plasminogen activator,
plasmin–antiplasmin complexes, plasminogen activa-
tor inhibitor and D-dimers. All samples were obtained
during hospitalization on 3 consecutive days, starting
on the day of admission, with a fourth and final sample
on day 7 or the day of discharge (survivors) or the day
before death (nonsurvivors).
The study protocol received approval from the
institutional Review Board of the University Hospital
of Diponegoro University in Semarang. Informed con-
sent was obtained from children’s parents or guardians
before inclusion in the study.
Diagnosis
The presence of dengue was objectively confirmed by
serological assays. A capture and indirect enzyme-
linked immunosorbent assay (ELISA) detected dengue-
specific IgM and IgG antibodies in serum samples
[Groen et al., 1999]. Dengue infections were defined as
primary when the ratio of dengue-specific IgM to IgG
serum antibodies was >1. When the ratio of dengue
specific IgM to IgG serum antibodies was <1, the
infections were defined as secondary dengue cases
[WHO, 1997]. Blood cultures were obtained in all
patients, to exclude bacterial infection.
Blood Collection
Venous blood (9 vol) for measurement of the activated
partial thromboplastin time, prothrombin time, fibrino-
gen, prothrombin fragment 1þ2, thrombin–antith-
rombin complexes, protein C and protein S and
D-dimers was drawn into Vacutainer tubes containing
0.105 M sodium citrate (1 vol) (Becton Dickinson, UK).
For measurement of plasmin–antiplasmin complexes,
tissue-type plasminogen activator and plasminogen
activator inhibitor, blood was collected in siliconized
Vacutainer tubes (Becton Dickinson) containing Poly-
brene (Janssen Chimica, Belgium) and EDTA (0.05%,
w/v, and 10 mM, respectively, final concentrations) to
prevent in vitro complex formation.
All blood samples were immersed immediately in
melting ice and subsequently centrifuged at 48C for
20 min at 1,600g. Plasma samples were stored at 708C
until assayed. Routine laboratory tests (hematology
and chemistry) were done in Indonesia. Research
assays were carried out on samples transported to the
Netherlands on dry ice.
Coagulation Assays
Fibrinogen concentrations (Clauss method), activa-
ted partial thromboplastin time and prothrombin time
were measured by means of a KC 10 (Sigma Aldrich,
Germany) mechanical coagulometer, using bovine
thrombin (Fibrinomat, bioMérieux, France), actin FS
(Dade Behring, Germany), and Thrombomat (bioMér-
ieux, France), respectively. Prothrombin fragment 1þ2
and thrombin–antithrombin complexes were deter-
mined by ELISA kits available commercially, according
to the manufacturer’s instructions (Enzygnost F1þ2
micro and TAT micro, Dade Behring, Marburg, Ger-
many). Protein C antigen and free and total protein S
antigen (with and without precipitation with PEG 25)
were assessed with sandwich-type ELISA kits accord-
ing to the manufacturer’s instructions (Stago Boehrin-
ger, Ingelheim, Germany; DAKO-ITK Diagnostics).
Fibrinolysis
For the measurement of D-dimer levels, the TintElize
D-dimer ELISA from Biopool (Sweden) was used, accor-
ding to the manufacturer’s instructions. Tissue-type
plasminogen activator and plasminogen activator inhi-
bitor were measured with sandwich ELISA kits, using
specific monoclonal antibodies as described by de Boer
et al. [1993]. Plasmin–antiplasmin complexes were
measured with a radioimmunoassay (RIA), as described
by Levi et al. [1992].
Statistical Analysis
The plasma levels of the analytes measured are
presented as median values with their corresponding
interquartile range. The Mann-Whitney U-test was
used to compare the respective plasma levels of pa-
tients who died during the study (nonsurvivors) with
those who recovered (survivors). The composition of the
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group changed and the number of patients became
limited, due to mortality. The level of statistical signi-
ficance of these data: two-tailed P-values of <0.05 were
considered to indicate statistical significance. Analyses
were performed using SPSS 9.0.
RESULTS
Patients
A total of 50 consecutive children with a clinical
diagnosis of dengue hemorrhagic fever were enrolled
in the study. The baseline characteristics of the sub-
groups, i.e., survivors and nonsurvivors, were similar
(Table I). All patients were of Javanese origin, exclud-
ing racial differences.
The serological assays confirmed dengue virus infec-
tions in all patients, either by an IgM response or by a
fourfold rise in IgG titers. Antibody profiles were typical
for secondary dengue virus infection, as only IgM to IgG
ratios of <1 were found.
Thirteen patients (26%) died during follow-up on the
intensive care unit with laboratory-proven DIC and
complications of shock. In all patients, blood cultures
showed no bacterial growth.
Coagulation
Activation of the coagulation system was more
pronounced in the deceased group than among survi-
vors (Table II). On admission, nonsurvivors had a more
pronounced prolongation of activated partial thrombo-
plastin time and prothrombin time than survivors,
suggesting activation of both the intrinsic pathway and
the extrinsic or tissue factor pathway. The activation
pattern is clearly manifested by an early increase in
markers of thrombin generation i.e. prothrombin
fragment 1þ2, thrombin–antithrombin complexes as
well as a diminished fibrinogen level. During follow-up,
these activation parameters tended to improve in the
survivor group but not in the deceased group (Table III).
In accordance with this activation pattern, the coagula-
tion inhibitor proteins C and S were lower among the
deceased than among survivors, also reflecting pro-
nounced activation of coagulation in the deceased
group.
Fibrinolysis
The fibrinolytic system was activated as reflected by
a rise in levels of tissue-type plasminogen activator,
plasmin–antiplasmin complexes and D-dimers in both
groups on day of admission (Table II). Tissue-type
plasminogen activator and D-dimer levels were in-
creased to a similar degree in both groups and
plasmin–antiplasmin complexes were found to be lower
in the nonsurvivor group compared with the survivor
group. Levels of plasminogen activator inhibitor, an
inhibitor of fibrinolysis, were initially (Table II) and
persistently (Table III) elevated in the deceased group
during the course of the disease, whereas there was a
slow decrease in plasminogen activator inhibitor levels
in the survivor group (Table III).
These data show that the fibrinolytic system, when
compared with the degree of activation of the coagula-
tion system, was relatively impaired in the nonsurvivor
group, resulting in an ongoing procoagulant state in
this group, as reflected by a high thrombin–antithrom-
bin to plasmin–antiplasmin ratio and lower levels of
circulating plasmin–antiplasmin complexes. In the sur-
vivor group, there was a switch to a profibrinolytic ratio
during the course of disease, reflected by a thrombin–
antithrombin to plasmin–antiplasmin ratio of < 1 on
the final day of follow-up.
TABLE I. Baseline Characteristics of the Patients Classified as Having Dengue
Hemorrhagic Fever Grade III and IV*
Survivors (n¼ 37) Nonsurvivors (n¼ 13)
Age (yr) 6.8 2.8 6.0 2.8
Female sex (%) 46% 69%
Admission day 4.3 0.9 4.1 1.4
Clinical diagnosis of dengue hemorrhgaic fever
Grade III (n) 34 9
Grade IV (n) 3 4
Thrombocytes ( 109/L) 63.9 35.7 48.7 12.9
Hematocrit (highest %) 38 6.4 36 7.4
White blood cell ( 109/L) 7.5 4.3 10.2 5.1
C-reactive protein 22.6 33.5 13.6 18.8
Pleural effusion
Right-sided (n) 12 3
Bilateral (n) 2 6
Lowest blood pressure
Systolic (mm Hg) 92 11 83 11
Diastolic (mm Hg) 59 24 45 31
Clammy skin (n) 3 6
Cold extremities (n) 35 13
*Values are reported as means with their corresponding standard deviation or numbers (n). Patients were
clinically diagnosed as dengue hemorrhagic fever grade III or IV, according the criteria of the World
Health Organization [WHO, 1997]. Normal values for hematocrit 33–40%; leukocytes 4–11 109/L;
thrombocytes 150–400 109/L.
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DISCUSSION
In the present study, it was demonstrated that severe
dengue hemorrhagic fever is characterized by activa-
tion of the coagulation and fibrinolytic systems,
reflected by both a rise in circulating levels of markers
of thrombin generation and markers of activation of
fibrinolysis. However, during the initial phase of infec-
tion these activation processes were not in balance
since thrombin–antithrombin to plasmin–antiplasmin
ratios were increased (ratio higher than 1), yielding a
procoagulant state. In survivors this procoagulant state
was counteracted by an activated protein C system, an
activated protein S system, and ongoing fibrinolysis,
resulting in a net anticoagulant state, as reflected by an
inverse thrombin–antithrombin to plasmin–antiplas-
min ratio (ratio < 1). In the nonsurvivor group such a
change from the procoagulant to the anticoagulant
state did not occur. Quite remarkably, plasminogen
activator inhibitor levels remained high during the
course of the disease in the deceased group, contribut-
ing to an ongoing procoagulant state by a relative
inhibition of fibrinolysis. The acquired protein C defi-
ciency observed in our patients may contribute to a
further enhancement of this procoagulant state and
hence to DIC and/or multiorgan failure.
Persistently high circulating plasminogen activator
inhibitor levels and increased thrombin–antithrombin
to plasmin–antiplasmin ratios were associated with an
adverse clinical outcome in our study. This phenom-
enon has also been observed in patients with systemic
bacterial infections [Brandtzaeg et al., 1990; Westen-
dorp et al., 1992; Kornelisse et al., 1996; Mesters et al.,
1996]. Studies of experimental bacterial sepsis models
demonstrated that specific cytokines mediate the de-
rangement of coagulation and fibrinolysis [ten Cate
et al., 1997]. Injection of endotoxin or tumor necrosis
factor (TNF) into healthy volunteers resulted in early
activation of fibrinolysis, as reflected by an early rise in
tissue-type plasminogen activator, which was rapidly
shut off by increasing levels of plasminogen activator
inhibitor [Suffredini et al., 1989]. Coagulation was also
activated early in these models and remained activated
for hours [Levi et al., 1997]. Hence, administration of
endotoxin or TNF induced a procoagulant state, char-
acterized by an increased thrombin–antithrombin to
plasmin–antiplasmin ratio [Suffredini et al., 1989]. A
similar procoagulant state has been described in
experimental studies of baboons with lethal sepsis [de
Boer et al., 1993]. In these experimental models,
coagulation and fibrinolysis appeared to be activated
independently, which may lead to an imbalance be-
tween fibrin formation and breakdown [van der Poll
et al., 1990]. Whether such a procoagulant state also
occurs in viral infections has not been investigated.
This study is the first to demonstrate such a mechanism
in patients with a severe viral infection.
Several issues in the present study merit further
comment. First, only patients with the severest form of
dengue hemorrhagic fever were investigated. Hence,
the findings are applicable only to patients with this
spectrum of disease. Huang et al. [2001] studied 25
patients with dengue fever and dengue hemorrhagic
fever. These investigators also found a deranged fibrin-
olytic system, as demonstrated by elevated levels of
tissue-type plasminogen activator and plasminogen
TABLE II. Markers of Coagulation and Fibrinolysis on Day of Admission in Patients With Dengue Hemorrhagic Fever
Grade III and IV{
All patients
(n¼ 50)
Survivors
(n¼ 37)
Nonsurvivors
(n¼ 13) Normal P*
Activated partial thromboplastin
time (sec)
52.0 (43.4–64.1) 47.6 (40.1–59.7) 71.1 (52.6–97.4) 24–36 0.001
Prothrombin time (sec) 13.2 (11.9–15.4) 12.6 (11.4–13.9) 16.3 (15.0–25.8) 10.5–13.5 0.001
Prothrombin fragment 1þ 2 (nmol/L) 3.2 (2.0–5.0) 2.8 (1.9–4.0) 4.9 (2.7–7.2) < 1.1 0.008
Thrombin–antithrombin
complexes (mg/L)
27.2 (13.3–65.7) 21.0 (10.9–52.0) 50.9 (28.5–117.5) < 4.1 0.004
Fibrinogen (g/L) 1.6 (1.3–1.9) 1.7 (1.5–2.1) 1.3 (0.8–1.6) 1.7–4.0 0.005
Protein C (%) 52.5 (36.8–66.3) 56.0 (48.0–68.0) 38.0 (10.0–63.5) 100% 0.04
Protein S activity (%) 51.0 (39.0–64.3) 54 (42.5–66.5) 34.0 (30.5–48.0) 100% 0.002
Protein S free (%) 23.0 (19.0–28.0) 23.0 (20.0–28.0) 18.0 (14.3–24.8) 100% 0.02
Tissue-type plasminogen
activator (ng/ml)
52.5 (41.0–61.0) 54.0 (41.0–61.0) 51.0 (25.0–69.0) < 10 0.93
Plasmin–antiplasmin
complexes (nmol)
8.6 (6.3–12.0) 10.0 (7.1–13.0) 6.4 (4.1–8.5) < 7 0.03
Plasminogen activator
inhibitor (ng/ml)
183.0 (86.8–392.5) 130.0 (65.0–280.5) 394.0 (270.0–1573.0) 30–60 0.001
D-Dimer (ng/ml) 241.0 (197.3–761.0) 234.0 (179.5–715.5) 301.0 (205.0–1303.0) < 39 0.23
Thrombin–antithrombin to
plasmin–antiplasmin ratio
2.8 (1.3–6.5) 2.3 (1.1–5.8) 7.8 (3.3–23.7) — 0.03
{Values of markers of coagulation and fibrinolysis on day of admission of all children (n¼ 50) with dengue hemorrhagic fever grade III and IV.
Values of the subgroup survivors (n¼ 37) and nonsurvivors (n¼ 13) are also given. The reported values are medians with their 25th and 75th
interquartile ranges.
*Denotes the resulted P-value after comparison of survivors and nonsurvivors, using the Mann-Whitney U-test.
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activator inhibitor, although the levels of plasminogen
activator inhibitor were 4- to 10-fold higher in our
series. Whether this is a result of differences in patient
baseline characteristics or the inclusion predominantly
of patients with mild dengue hemorrhagic fever
remains to be determined. Second, all the enrolled
patients who were classified clinically as having dengue
hemorrhagic fever on the basis of widely accepted
clinical criteria had serologically confirmed dengue
virus infections. This occurred despite the inclusion of
consecutive patients in order to avoid selection bias and
explains the lack of a non-dengue control group in this
study.
Allotypic variations in the promoter region of the
plasminogen activator inhibitor gene may contribute to
inter-individual variations in plasminogen activator
inhibitor responses [Eriksson et al., 1995]. In patients
with meningococcal disease, these allotypic variations
are associated with an enhanced risk of septic shock
after infection with Neisseria meningitides [Westen-
dorp et al., 1999]. It is speculated that these allotypic
variations of the plasminogen activator inhibitor gene
may also be associated with the severity of dengue
hemorrhagic fever. In addition, other genetic poly-
morphisms, such as those involved in the production
and release of cytokines, may contribute to the outcome
of dengue virus infections [Westendorp et al., 1994; van
Dissel et al., 1998]. The role of genetic factors in the risk
of developing severe dengue hemorrhagic fever is the
subject of present prospective studies.
In conclusion, severe dengue hemorrhagic fever is
associated with a relative impaired fibrinolytic response
as a result of elevated circulating plasminogen activa-
tor inhibitor levels, which may contribute to a high
mortality. In addition, high levels of plasminogen acti-
vator inhibitor and elevated thrombin–antithrombin to
plasmin–antiplasmin ratios may be used as prognostic
markers in daily management. The procoagulant state
demonstrated may be a target for future intervention
among patients with this disease.
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